Results 11 to 20 of about 3,573 (200)

Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry-Based Real-World Study. [PDF]

Eur J Neurol
ABSTRACT Background Recent post‐marketing studies have indicated a possible association between anti‐CGRP receptor monoclonal antibodies (anti‐CGRP‐mAbs) used for migraine prophylaxis and an increased risk of hypertension (HT). Methods We performed a retrospective real‐world exploratory study, including individuals with a confirmed diagnosis of ...
Lampl C, Suliman R, Tischler-Strasser V, MaassenVanDenBrink A, Alsaadi T.   +4 more
europepmc   +2 more sources

A Real-World Study of CGRP Monoclonal Antibodies for Migraine: Long-Term Effectiveness and Treatment Adherence. [PDF]

Eur J Neurol
In our 24‐month real‐world study, the mean monthly migraine days (MMDs) significantly decreased from baseline by 6.8, 7.9, 8.7, and 10.0 days at Months 3, 6, 12, and 24, respectively (all p < 0.001). Significant reductions were also observed across all time points in both episodic migraine and chronic migraine subgroups.
Suzuki K, Suzuki S, Kobayashi S, Shioda M, Fujita H, Haruyama Y, Hirata K.   +6 more
europepmc   +2 more sources

Interventions for Migraine and Sleep: A Systematic Review Exploring Their Bidirectional Association. [PDF]

Eur J Neurol
ABSTRACT Background Migraine and sleep disturbances share a bidirectional relationship, influencing each other's frequency and severity. The aim of this systematic review is to examine the effects of migraine‐targeted interventions on both migraine outcomes and sleep parameters (including sleep quality and insomnia symptoms), as well as the effects of ...
Sforza M, Mariani I, Fazzini F, Genovese F, Salibba A, Filippi M, Proserpio P, Galbiati A, Messina R, Ferini-Strambi L.   +9 more
europepmc   +2 more sources

Predictors of response to erenumab after 12 months of treatment [PDF]

, 2021
Objective: Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor and approved for the preventive treatment of chronic migraine.
Baraldi, Carlo, Cainazzo, Maria Michela, Castro, Flavia Lo, Guerzoni, Simona, Pani, Luca   +4 more
core   +5 more sources

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

Pain and Therapy, 2021
Introduction Erenumab is indicated for migraine preventive treatment in adults. The objective of this study was to provide descriptive information on real-world use of erenumab including patient profile and treatment patterns.
David Chandler, Christine Szekely, Shivani Aggarwal, Lori Cyprien, Mark Bensink   +4 more
doaj   +1 more source

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE

BMC Neurology, 2022
Background Erenumab is a fully human monoclonal antibody and a highly potent, first-in-class calcitonin gene-related peptide receptor inhibitor approved for migraine prevention in adults. Randomised, placebo-controlled trials show that erenumab treatment
Taoufik Alsaadi, Suzan Noori, Razmig Varakian, Saly Youssef, AbuBaker Almadani   +4 more
doaj   +1 more source

Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials

The Journal of Headache and Pain, 2022
Background Erenumab, a fully human monoclonal antibody that targets the calcitonin gene-related peptide receptor, has demonstrated efficacy and safety in the prevention of episodic and chronic migraine.
Christian Lampl, Viktoria Kraus, Katrina Lehner, Brett Loop, Mahan Chehrenama, Zofia Maczynska, Shannon Ritter, Jan Klatt, Josefin Snellman   +8 more
doaj   +1 more source

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study

Frontiers in Neurology, 2023
BackgroundTherapeutic options for migraine prevention in non-responders to monoclonal antibodies (mAbs) targeting Calcitonin Gene-Related Peptide (CGRP) and its receptor are often limited.
Lucas Hendrik Overeem, Lucas Hendrik Overeem, Kristin Sophie Lange, Mira Pauline Fitzek, Anke Siebert, Maureen Steinicke, Paul Triller, Ja Bin Hong, Uwe Reuter, Uwe Reuter, Bianca Raffaelli, Bianca Raffaelli   +11 more
doaj   +1 more source

A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

The Journal of Headache and Pain, 2022
Abstact Background DRAGON was a phase 3, randomised, double-blind, placebo-controlled study which evaluated the efficacy and safety of erenumab in patients with chronic migraine (CM) from Asia not adequately represented in the global pivotal CM study ...
Shengyuan Yu, Byung-Kun Kim, Hebo Wang, Jiying Zhou, Qi Wan, Tingmin Yu, Yajun Lian, Michal Arkuszewski, Laurent Ecochard, Shihua Wen, Fangfang Yin, Zheng Li, Wendy Su, Shuu-Jiun Wang   +13 more
doaj   +1 more source

Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab

The Journal of Headache and Pain, 2022
Background Migraine involves central and peripheral nervous system mechanisms. Erenumab, an anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody with little central nervous system penetrance, is effective for migraine prevention.
Todd J. Schwedt, Simona Nikolova, Gina Dumkrieger, Jing Li, Teresa Wu, Catherine D. Chong   +5 more
doaj   +1 more source